Elfunat

Efficiency of methods of postoperative correction of metabolic homeostasis in patients with acute peritonitis
Published in a journal «Pain, Anaesthesia and Intensive Care» № 2 (83)’2018
Elfunate in the treatment of patients with discirculatory encephalopathy
Published in the journal «Neurology and Neurosurgery. Eastern Europe» Vol 7 № 3’2017
Combined therapy with Medotilin and Elfunat in the prevention and treatment of neuropsychiatric complications after open heart surgery
Regional Center of Cardiosurgery of Odesa Regional Hospital, Odesa, Ukraine
Features of management of patients with community-acquired pneumonia with concomitant pathology: substantiation of the advisability of using antihypoxants on the example of ethylmethylhydroxypyridine succinate
Published in a journal «Emergency Medicine» Vol 17 № 5’2021
Elfunat in the holiatry of patients with portal gipertenziey in an early postgemorragicheskom period
Published in the journal «Emergency Medicine» Vol 17 № 3’2021
Features of cognitive violations at COVID-19
Published in the journal «International neurological journal» Vol 17 № 3’2021
Use of Medotilin and Elfunat in acute and subacute period of ischemic stroke
Published in a journal «Neurology and neurosurgery. Eastern Europe» Vol 7 № 3’2017
Possibilities of neuroprotection in the complex therapy of traumatic brain injury
Published in the journal “Emergency Medicine” № 7 (78) '2016

CARD-NOTIFICATION OF AN ADVERSE DRUG REACTION AND/OR LACK OF EFFICACY OF THE MEDICINE

INFORMATION ABOUT THE PATIENT

SUSPECTED AR/LE

Suspected AR (describe each clinical manifestation of the AR with dates and times of onset and end and outcome)/Indication of the LE

INFORMATION ABOUT SUSPECTED MEDICINES

INFORMATION ABOUT RELATED MEDICINES

(with the exception of drugs used to correct the effects of AR/LE)
(concomitant diagnoses, laboratory and instrumental studies, allergy history, pregnancy with gestational age, method of conception, pregnancy outcome (if the pregnancy ended, the date of delivery, type of delivery, etc.)

Information about the messenger

INFORMATION ABOUT THE MEDICAL/PHARMACY SPECIALIST

(if not the notifier)

MESSAGE CARD for the patient

to provide the patient and/or his/her representative with information on adverse drug reactions and/or lack of efficacy of the drug

INFORMATION ABOUT THE PATIENT

Information about the suspected medicine

Information on the prescription of the suspected medicinal product

Information about the messenger

Information about the physician, healthcare facility and place of residence of the patient who had an adverse medicine reaction and/or lack of efficacy of the medicine

розробка сайту Estetic web design